Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Appointed director
CC transcript

Synaptogenix, Inc. (SNPX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/19/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Synaptogenix and Cleveland Clinic to Submit Investigational New Drug Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis"
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/28/2023 8-K Quarterly results
04/14/2023 8-K Quarterly results
03/31/2023 4 SCHECHTER JONATHAN (Director) has filed a Form 4 on Synaptogenix, Inc.
Txns: Granted 20,000 options to buy @ $0.87, valued at $17.4k
03/31/2023 4 Singer William S. (Director) has filed a Form 4 on Synaptogenix, Inc.
Txns: Granted 20,000 options to buy @ $0.87, valued at $17.4k
03/31/2023 4 Bernstein Bruce (Director) has filed a Form 4 on Synaptogenix, Inc.
Txns: Granted 20,000 options to buy @ $0.87, valued at $17.4k
03/31/2023 4 Silverman Joshua (Director) has filed a Form 4 on Synaptogenix, Inc.
Txns: Granted 20,000 options to buy @ $0.87, valued at $17.4k
03/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/21/2023 10-K Annual Report for the period ended December 31, 2022
03/20/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/07/2023 8-K Results of Operations and Financial Condition  Interactive Data
02/08/2023 SC 13G/A INTRACOASTAL CAPITAL, LLC reports a 10% stake in Synaptogenix, Inc.
01/18/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/09/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
12/28/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
12/28/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
12/28/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
12/20/2022 4 Singer William S. (Director) has filed a Form 4 on Synaptogenix, Inc.
Txns: Sold 27,000 shares @ $1.1719, valued at $31.6k
12/20/2022 4 WEINSTEIN ROBERT (CFO) has filed a Form 4 on Synaptogenix, Inc.
Txns: Sold 27,000 shares @ $1.1719, valued at $31.6k
12/20/2022 4 Silverman Joshua (Director) has filed a Form 4 on Synaptogenix, Inc.
Txns: Sold 19,012 shares @ $1.1719, valued at $22.3k
12/20/2022 4 SCHECHTER JONATHAN (Director) has filed a Form 4 on Synaptogenix, Inc.
Txns: Sold 20,250 shares @ $1.1719, valued at $23.7k
12/20/2022 4 Alkon Daniel L. (President and CSO) has filed a Form 4 on Synaptogenix, Inc.
Txns: Sold 19,688 shares @ $1.1719, valued at $23.1k
12/20/2022 4 Bernstein Bruce (Director) has filed a Form 4 on Synaptogenix, Inc.
Txns: Sold 22,500 shares @ $1.1719, valued at $26.4k
12/20/2022 4 TUCHMAN ALAN J (CEO) has filed a Form 4 on Synaptogenix, Inc.
Txns: Sold 27,000 shares @ $1.1719, valued at $31.6k
12/16/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
12/16/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
12/01/2022 4/A WEINSTEIN ROBERT (CFO) has filed a Form 4 on Synaptogenix, Inc.
Txns: Granted 75,000 options to buy @ $6.07, valued at $455.3k
12/01/2022 4/A Alkon Daniel L. (President and CSO) has filed a Form 4 on Synaptogenix, Inc.
Txns: Granted 43,750 shares @ $0
12/01/2022 4/A Silverman Joshua (Director) has filed a Form 4 on Synaptogenix, Inc.
Txns: Granted 42,250 shares @ $0
12/01/2022 4/A Singer William S. (Director) has filed a Form 4 on Synaptogenix, Inc.
Txns: Granted 75,000 options to buy @ $6.07, valued at $455.3k
12/01/2022 4/A Silverman Joshua (Director) has filed a Form 4 on Synaptogenix, Inc.
Txns: Granted 75,000 options to buy @ $6.07, valued at $455.3k
12/01/2022 4/A Alkon Daniel L. (See Remark) has filed a Form 4 on Synaptogenix, Inc.
Txns: Granted 75,000 options to buy @ $6.07, valued at $455.3k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy